Outcome measures in neuromuscular disease: Is the world still flat?

Journal of the Peripheral Nervous System

Volumn 20, Issue 3, 2015, Pages 255-259

  Lunn, Michael P ^a   Van Den Bergh, Peter Y K ^b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

anchoring; cognitive bias; knowledge; outcome measures; Rasch

Indexed keywords

CHEMOTHERAPY INDUCED NEUROPATHY; CLINICAL DECISION MAKING; FAMILIAL AMYLOID POLYNEUROPATHY; FUNCTIONAL STATUS ASSESSMENT; HUMAN; INFLAMMATORY RASCH BUILT OVERALL DISABILITY SCORE; ITEM RESPONSE THEORY; MOTOR DYSFUNCTION ASSESSMENT; MOTOR NEUROPATHY; NEUROLOGIC DISEASE ASSESSMENT; NEUROMUSCULAR DISEASE; NEUROPATHY; NEUROPATHY IMPAIRMENT SCORE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASCH ANALYSIS; RASCH TRANSFORMED MRC SCALE; RASCH TRANSFORMED NEUROPATHY IMPAIRMENT SCORE; RASCH TRANSFORMED TOTAL NEUROPATHY SCORE; REVIEW; SMALL FIBER NEUROPATHY; THEORY; NEUROMUSCULAR DISEASES;

HUMANS; NEUROMUSCULAR DISEASES; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84942591875     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/jns.12119     Document Type: Review

References (22)

1. Ariely D, (2008). Predictably Irrational: The Forces That Shape Our Decisions. Harper Collins, New York.
2. ©) in patients with chemotherapy-induced peripheral neuropathy. J Peripher Nerve Syst 20: 328-332.
3. Brouwer BA, Bakkers M, Hoeijmakers JGJ, Faber CG, Merkies ISJ, (2015). Improving assessment in small fiber neuropathy. J Peripher Nerve Syst 20: 333-340.
4. Dalakas MC, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, McElroy B, (2009). Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 65: 286-293.
5. Draak TH, Vanhoutte EK, van Nes SI, Gorson KC, van der Pol WL, Notermans NC, Nobile-Orazio E, Leger JM, Van den Bergh PY, Lauria G, Bril V, Katzberg H, Lunn MP, Pouget J, van der Kooi AJ, Hahn AF, Doorn PA, Cornblath DR, Van den Berg LH, Faber CG, Merkies IS, (2014). Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness. Neurology 83: 2124-2132.
6. Draak THP, Vanhoutte EK, van Nes SI, Gorson KC, Van der Pol W-L, Notermans NC, Nobile-Orazio E, Lewis RA, Léger JM, Van den Bergh PYK, Lauria G, Bril V, Katzberg H, Lunn MPT, Pouget J, van der Kooi AJ, Hahn AF, van den Berg LH, van Doorn PA, Cornblath DR, Faber CG, Merkies ISJ,; on behalf of the PeriNomS study group (2015). Comparing the NIS vs MRC and INCAT sensory scale through Rasch analyses. J Peripher Nerve Syst 20: 276-287.
7. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, Wilson DM, O'Brien PC, Melton LJ III, Service FJ, (1993). The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 43: 817-824.
8. Dyck PJ, Boes CJ, Mulder D, Millikan C, Windebank AJ, Dyck PJ, Espinosa R, (2005). History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation. J Peripher Nerv Syst 10: 158-173.
9. Gettier EL, (1963). Is justified true belief knowledge? Analysis 23: 121-123.
10. Hilton J, (2014). Results should not be reported as statistically significant or statistically non-significant. http://editorial&unit.cochrane.org/blog/results&should¬&be&reported&as&statistically&significant&or&statistically&non&significant.
11. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM, (1978). Controlled trial prednisolone in acute polyneuropathy. Lancet 2: 750-753.
12. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC, (1992). Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 327: 248-254.
13. Leger JM, Viala K, Nicolas G, Creange A, Vallat JM, Pouget J, Clavelou P, Vial C, Steck A, Musset L, Marin B, (2013). Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 80: 2217-2225.
14. van Nes SI, Vanhoutte EK, van Doorn PA, Hermans M, Bakkers M, Kuitwaard K, Faber CG, Merkies IS, (2011). Rasch-built overall disability scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 76: 337-345.
15. Pruppers MHJ, Draak THP, Vanhoutte EK, Van der Pol W-L, Gorson KC, Léger J-M, Nobile-Orazio E, Lewis RA, van den Berg LH, Faber CG, Merkies ISJ,; on behalf of the PeriNomS study group (2015a). Outcome measures in MMN revisited: further improvement needed. J Peripher Nerve Syst 20: 306-318.
16. ©). J Peripher Nerve Syst 20: 319-327.
17. Rasch G, (1992). Probabilistic Models for Some Intelligence and Attainment Tests. University of Chicago Press, Chicago.
18. Tversky A, Kahneman D, (1974). Judgment under uncertainty: heuristics and biases. Science 185: 1124-1131.
19. Vanhoutte EK, Faber CG, van Nes SI, Jacobs BC, van Doorn PA, van Koningsveld R, Cornblath DR, van der Kooi AJ, Cats EA, Van den Berg LH, Notermans NC, van der Pol WL, Hermans MC, van der Beek NA, Gorson KC, Eurelings M, Engelsman J, Boot H, Meijer RJ, Lauria G, Tennant A, Merkies IS, (2012). Modifying the Medical Research Council grading system through Rasch analyses. Brain 135: 1639-1649.
20. Vanhoutte EK, Hermans MCE, Faber CG, Gorson KC, Merkies ISJ, Thonnard J-L,; on behalf of the PeriNomS Study Group (2015a). Rasch-ionale for neurologists. J Peripher Nerve Syst 20: 260-268.
21. ©). J Peripher Nerve Syst 20: 296-305.
22. WHO (2011) World report on disability 2011. http://www.who.int/disabilities/world-report/2011/en/ (Accessed August 21, 2015).